Brief: Absci Initiates IND-Enabling Studies for ABS-101
Feb 21 (Reuters) - Absci Corp ABSI.O :
* ABSCI INITIATES IND-ENABLING STUDIES FOR ABS-101, A
POTENTIAL
BEST-IN-CLASS ANTI-TL1A ANTIBODY DE NOVO DESIGNED AND OPTIMIZED
USING GENERATIVE AI
* ABSCI CORP - ABSCI EXPECTS TO SUBMIT AN IND FOR ABS-101 IN
Q1 OF
2025
Source text for Eikon: ID:nGNX66fkGl
Further company coverage: ABSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbSci
See all newsAbsci Corp reports results for the quarter ended September 30 - Earnings Summary
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave